Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin.
Slightly overvalued with limited growth.
Share Price & News
How has Biofrontera's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: B8F has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: B8F underperformed the German Biotechs industry which returned 9% over the past year.
Return vs Market: B8F underperformed the German Market which returned 14.4% over the past year.
Price Volatility Vs. Market
How volatile is Biofrontera's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Biofrontera undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: B8F (€5.34) is trading below our estimate of fair value (€37.36)
Significantly Below Fair Value: B8F is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: B8F is poor value based on its PE Ratio (263.4x) compared to the Biotechs industry average (39.4x).
PE vs Market: B8F is poor value based on its PE Ratio (263.4x) compared to the German market (20.7x).
Price to Earnings Growth Ratio
PEG Ratio: B8F's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: B8F is overvalued based on its PB Ratio (16.1x) compared to the DE Biotechs industry average (3.6x).
How is Biofrontera forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: B8F's earnings are forecast to decline over the next 3 years (-161.1% per year).
Earnings vs Market: B8F's earnings are forecast to decline over the next 3 years (-161.1% per year).
High Growth Earnings: B8F's earnings are forecast to decline over the next 3 years.
Revenue vs Market: B8F's revenue (34.6% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: B8F's revenue (34.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if B8F's Return on Equity is forecast to be high in 3 years time
How has Biofrontera performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: B8F has a large one-off gain of €14.8M impacting its September 30 2019 financial results.
Growing Profit Margin: B8F became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: B8F has become profitable over the past 5 years, growing earnings by 9.8% per year.
Accelerating Growth: B8F has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: B8F has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: B8F's Return on Equity (5.8%) is considered low.
Return on Assets
Return on Capital Employed
How is Biofrontera's financial position?
Financial Position Analysis
Short Term Liabilities: B8F's short term assets (€32.4M) exceed its short term liabilities (€16.3M).
Long Term Liabilities: B8F's short term assets (€32.4M) do not cover its long term liabilities (€41.9M).
Debt to Equity History and Analysis
Debt Level: B8F's debt to equity ratio (135.6%) is considered high.
Reducing Debt: B8F's debt to equity ratio has reduced from 432.1% to 135.6% over the past 5 years.
Inventory Level: B8F has a low level of unsold assets or inventory.
Debt Coverage by Assets: B8F's debt is covered by short term assets (assets are 1.7x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: B8F is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: B8F is profitable, therefore cash runway is not a concern.
What is Biofrontera's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate B8F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate B8F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if B8F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if B8F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of B8F's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Hermann Lübbert (63yo)
Prof. Hermann Lübbert, Ph.D. is a Co-Founder of Biofrontera AG and serves as its Chief Executive Officer since 1997and Chairman of Management Board since 2000. Prof. Lübbert serves as the Chief Scientific ...
CEO Compensation Analysis
Compensation vs Market: Hermann's total compensation ($USD785.49K) is about average for companies of similar size in the German market ($USD625.38K).
Compensation vs Earnings: Hermann's compensation has been consistent with company performance over the past year.
|CFO & Member of the Executive Board||6.7yrs||€511.64k||0.13% €302.8k|
|Head of Investor Relations||0yrs||no data||no data|
|Head of UK Sales Team||1.8yrs||no data||no data|
|Head of Sales & Marketing - Europe||0.08yrs||no data||no data|
Experienced Management: B8F's management team is considered experienced (4.2 years average tenure).
|Member of the Supervisory Board||3.8yrs||€15.00k||no data|
|Head of the Scientific Advisory Board||0yrs||no data||no data|
|Vice-Chairman of the Supervisory Board||3.8yrs||€22.50k||0.067% €153.3k|
|Member of the Supervisory Board||2yrs||€13.75k||no data|
|Chairman of the Supervisory Board||3.8yrs||€30.00k||no data|
|Member of Supervisory Board||3.8yrs||€15.00k||0.011% €25.6k|
|Member of Supervisory Board||0.6yrs||no data||no data|
Experienced Board: B8F's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Biofrontera AG's company bio, employee growth, exchange listings and data sources
- Name: Biofrontera AG
- Ticker: B8F
- Exchange: DB
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €229.009m
- Shares outstanding: 44.82m
- Website: https://www.biofrontera.com
Number of Employees
- Biofrontera AG
- Hemmelrather Weg 201
- North Rhine-Westphalia
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|B8F||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2006|
|B8F||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Oct 2006|
|0DOL||LSE (London Stock Exchange)||Yes||Common Stock||GB||EUR||Oct 2006|
|B8Fd||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Common Stock||GB||EUR||Oct 2006|
|BFFT.F||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Oct 2006|
|B8F||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Oct 2006|
|B8FE||BST (Boerse-Stuttgart)||SPON ADS EACH REP TWO ORD||DE||EUR||Feb 2018|
|BFRA||NasdaqCM (Nasdaq Capital Market)||SPON ADS EACH REP TWO ORD||US||USD||Feb 2018|
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company’s product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of mild to moderate acne. The company offers its products primarily in the United States, Europe, and Israel. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 21:10|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.